share_log

Eli Lilly's Options: A Look at What the Big Money Is Thinking

Benzinga ·  Jan 7 22:45

Investors with a lot of money to spend have taken a bullish stance on Eli Lilly (NYSE:LLY).

And retail traders should know.

We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.

Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with LLY, it often means somebody knows something is about to happen.

So how do we know what these investors just did?

Today, Benzinga's options scanner spotted 14 uncommon options trades for Eli Lilly.

This isn't normal.

The overall sentiment of these big-money traders is split between 50% bullish and 21%, bearish.

Out of all of the special options we uncovered, 6 are puts, for a total amount of $810,104, and 8 are calls, for a total amount of $355,436.

Predicted Price Range

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $330.0 to $960.0 for Eli Lilly during the past quarter.

Volume & Open Interest Trends

Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Eli Lilly's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eli Lilly's whale trades within a strike price range from $330.0 to $960.0 in the last 30 days.

Eli Lilly Option Activity Analysis: Last 30 Days

bigjpg

Largest Options Trades Observed:

SymbolPUT/CALLTrade TypeSentimentExp. DateAskBidPriceStrike PriceTotal Trade PriceOpen InterestVolume
LLYPUTTRADEBULLISH01/15/27$75.9$73.5$73.5$670.00$514.5K9870
LLYCALLTRADEBULLISH04/17/25$14.3$14.0$14.3$900.00$357.5K222250
LLYPUTTRADEBEARISH12/18/26$73.1$65.6$71.0$670.00$142.0K11920
LLYCALLTRADEBULLISH01/17/25$435.0$430.0$435.0$330.00$87.0K942
LLYPUTTRADEBULLISH01/16/26$109.1$104.25$105.29$800.00$52.6K1.6K5

About Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Current Position of Eli Lilly

  • With a trading volume of 194,553, the price of LLY is up by 0.26%, reaching $767.07.
  • Current RSI values indicate that the stock is may be approaching oversold.
  • Next earnings report is scheduled for 30 days from now.

What Analysts Are Saying About Eli Lilly

A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $997.0.

Turn $1000 into $1270 in just 20 days?

20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access.* Reflecting concerns, an analyst from B of A Securities lowers its rating to Buy with a new price target of $997.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment